openPR Logo
Press release

New Report: Hyperlipidemia Drug Market 2019 Size, Growth Analysis Report, Forecast to 2025

09-14-2021 09:25 AM CET | Health & Medicine

Press release from: Orion Market Reports

The global hyperlipidemia drug market is estimated to witness significant growth during the forecast period. The demand for a statin to manage cholesterol is driving the market growth across the globe. This drug supports lowering cholesterol, hence reduce the chances of cardiovascular diseases, stroke, and diabetes. Statins are used to manage the plaque on blood vessels and reduce the risk of blood clots. There are various statins options are available in the market for lowering cholesterol levels. Some of the statins used in the US include Atorvastatin (Lipitor), Lovastatin (Altoprev), Pitavastatin (Livalo, Zypitamag), Pravastatin (Pravachol), Rosuvastatin (Crestor, Ezallor), and Simvastatin (Zocor).

(Get 15% Discount on Buying this Report)
Get Report Sample Copy @

Further, according to the American Heart Association (AHA), historical data shows 79.8% of adults who were at least 40 years old use of statins for lowering cholesterol from 2002 to 2013 studies. Such an extensive rise in the number of statinusers is driving the growth of the hyperlipidemia drug market. However, increasing side effects associated withstatin drugs is expected to hinder the growth of the statin drug market. Statins drugs have side effects and some patients are unable to bear it. For instance, atorvastatin and rosuvastatin are high-intensity statins which cause rare side effects like new-onset diabetes and muscle symptoms.

A Full Report of Global IoT Sensors Market is Available at:

Hence, the demand for non-statin drugs is expected to contribute to hyperlipidemia drug market growth in the near future. In 2020, the FDA has approved two non-statin drugs after a long period of the last 2 decades. For instance, in February 2020, The FDA approved the first non-statin oral medication for high cholesterol commercialized in the US and around the world. The drug, bempedoic acid, is the first in a new class of drugs to treat low-density-lipoprotein cholesterol.

Further, in February 2020, Esperion Therapeutics Inc received FDA approval for its Nexletol, a new type of cholesterol-lowering drug. This drug will help people manage their high cholesterol and reduce the risk of heart diseases. Further, other non-statin drugs for lowering cholesterol include PCSK9-targeting drugs such as Amgen’s Repatha (evolocumab), Sanofi’s Praluent (alirocumab) and inclisiran, developed by Alnylam Pharmaceuticals and The Medicines Company and currently under FDA review.

Global Hyperlipidemia Drug Market Segmentation

By Drug Class
• HMG-CoA Reductase Inhibitors (Statins)
• PCSK9 Inhibitors
• Cholesterol Absorption Inhibitors
• Fabric Acid Derivatives (Fibrates)
• Niacin (Nicotinic Acid)
• Bile Acid Sequestrants (BAS)
• Combination Therapy and Compliance
• Others

Global Hyperlipidemia Drug Market Segmentation by region

North America
• United States
• Canada

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

• China
• Japan
• India
• Rest of the Asia-Pacific

Rest of the World
• Middle East & Africa
• Latin America

Company Profiles
• Abbott Laboratories
• Amgen, Inc.
• AstraZeneca PLC
• Bristol-Myers Squibb Co.
• Daiichi Sankyo Co., Ltd.
• Dr.Reddy's Laboratories, Ltd.
• GlaxoSmithKline PLC

Reasons to Buying From us –

1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.

For More Customized Data, Request for Report Customization @

Media Contact:

Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Contact no: +91 780-304-0404

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release New Report: Hyperlipidemia Drug Market 2019 Size, Growth Analysis Report, Forecast to 2025 here

News-ID: 2391671 • Views: 87

More Releases from Orion Market Reports

Pancreatic Cancer Therapy Market Size, Share, Growth, Trends, Analysis and Forec …
The Global Pancreatic Cancer Therapy Market is expected to reach US$ 4,056.4 Mn in 2027 from US$ 2,011.2 Mn in 2017. The market is estimated to grow with a CAGR of 8% from 2021-2027. Pancreatic cancer begins when cells in the pancreas grow out of control. Pancreatic cancer can be divided into two types, exocrine tumors and endocrine tumors, depending on the type of cells affected. These tumors behave differently. So
Insulin Pumps Market Analysis By Industry Size, Share, Revenue Growth and Demand …
The Global Insulin Pumps Market size was valued at 3.30 billion in 2018 and is projected to expand at a CAGR of 9% during the forecast period 2021-2027. Insulin pumps are used to control insulin in people with diabetes at specific intervals. An insulin pump is attached to the person's body and insulin is administered through a catheter inserted under the skin. The pump delivers a certain amount of insulin to
Surgical Suture Market By Size, Demand Analysis, Type, Statistics, Regions and F …
The Global Surgical Suture Market is projected to reach USD 4.9 billion by 2026 from USD 3.7 billion in 2021, at a CAGR of 6% from 2021 to 2027. Surgical sutures, commonly called needles, use a needle to which a length of thread is attached. Surgical sutures are used to close wounds such as skin ulcers, neuropathic ulcers, pediatric heart surgery, and diabetic ulcers. These sutures cause less reaction and provide
Bone Cement Market Size, Share, Analysis, Applications, Growth Insight, Trends, …
The Global Bone Cement Market was valued at about USD 1.2 billion in 2020. The industry is further anticipated to grow at a CAGR of 8% to attain a value of USD 1.9 billion by 2027 over the forecast period of 2021-2027. Bone cement is used by surgeons to secure implants in various orthopedic and traumatic surgeries. Bone cement acts as a filler to create a narrow space that holds the

All 5 Releases

More Releases for FDA

FDA Compliant Blood Storage and Preservation
Accsense Monitoring System Automates Data Archive and Alarming CAS DataLoggers provided the temperature alarming and monitoring system to a hospital blood bank looking to replace their old paper chart recorders as they became unreliable and spare parts were harder to find. For proper blood storage and preservation, the lab’s medical units needed to maintain storage temperatures between 2°C to 6°C (36°F to 43°F), given the perishability of blood components. The facility
Peyronie’s Disease Market - Only FDA approved product
The market is dominated by a single player, Endo International plc who sells the only FDA approved Peyronie’s disease product. In May 2015, the American Urological Association presented the first ever treatment guidelines for Peyronie’s disease recommending the use of Xiaflex. Furthermore, the company is creating awareness through its “Ask About the Curve” campaign. Also, reimbursement from the U.S. insurance providers will boost the demand for this product. The product
FDA grants orphan drug status to Vicore
US Food and Drug Administration has awarded Vicore Pharmaceuticals with orphan Drug designation for the treatment of Idiopathic Pulmonary Fibrosis (IPF). FDA’s Orphan Drug Designation program provides certain incentives for companies developing therapeutics to treat rare diseases or conditions, defined as those affecting less than 200,000 individuals in the U.S. A drug candidate and its sponsor must meet several key criteria in order to qualify for, and obtain, orphan drug
New FDA Design Control Training Courses
Salt Lake City, Utah - February 23 2017 - Procenius Consulting is a medical device consulting firm specializing solely in medical device design controls regulation (21 CFR 820.30). Announcing New Design Control Training Courses Procenius Consulting has just launched two new training courses covering basic and advanced topics of medical device design control regulation. These courses focus on compliance, practical implementation and industry best practices techniques for developing or improving a
fda online training
GRC Training Solutions provides end-to-end FDA compliance solutions for those companies who want to maximize security, minimize operational costs, improve staff productivity and stay on top of all their compliance documentation. GRC Training Solutions boasts a team of experts and specialists who have a proven track record in working with the biotechnology, medical device, diagnostic and pharmaceutical fields. Our team will work with you closely and develop solutions that meet
11-09-2016 | Science & Education
FDA online training
Description: Device firms, establishments or facilities that are involved in the production and distribution of medical devices intended for use in the U.S are required to register annually. Most establishments that are required to register with the FDA are also required to list the devices that are made there and the activities that are performed on those devices. Initially, FDA issued a 28-page Proposed Rule that would amend its regulations regarding